Core Viewpoint - Huaren Pharmaceutical announced the approval of its subsidiary Anhui Hengxing Pharmaceutical's application for the chemical raw material "Nafamostat Mesilate" by the National Medical Products Administration [2] Group 1 - The approval notification for "Nafamostat Mesilate" marks a significant milestone for Huaren Pharmaceutical and its subsidiary [2] - This approval allows the company to expand its product offerings in the pharmaceutical market [2] - The development reflects the company's ongoing commitment to innovation and compliance with regulatory standards [2]

Core Viewpoint - Huaren Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for its subsidiary Anhui Hengxing Pharmaceutical to market "Nefopam Hydrochloride," a non-narcotic, non-addictive analgesic drug [1] Group 1: Product Approval - Anhui Hengxing Pharmaceutical has been granted the "Chemical Raw Material Drug Marketing Application Approval Notice" for Nefopam Hydrochloride, with notification number 2025YS00762 [1] Group 2: Product Characteristics - Nefopam Hydrochloride is a powerful analgesic with mild antipyretic and muscle relaxant effects, primarily used for treating acute pain, especially postoperative pain [1] - The drug can also serve as an adjunct in local anesthesia and needle anesthesia [1] - It is not classified as a psychoactive analgesic, thus eliminating concerns regarding addiction [1] Group 3: Clinical Usage - Nefopam Hydrochloride has been widely used in clinical settings for severe pain due to its effective pain relief, minimal side effects, and characteristics of rapid onset and prolonged action [1]